|
Dr. Callaghan joined Eli Lilly and Company in 1979 as a clinical pharmacologist with responsibility for leading drug development projects through Phase 1 clinical trails. He was also appointed Assistant Professor of Medicine and Pharmacology at Indiana University School of Medicine in 1979. He led the clinical pharmacology teams involved successful NDAs for nizatidine (H2-antagonist), pinacidil (K channel opener), and olanzapine (an atypical antipsychotic). He has experience developing drugs in the fields of cardiology, gastroenterology, psychiatry, pulmonary, rheumatology, infectious disease, diabetes, and opiate pharmacology. In 1999 he was appointed Director of the Lilly Clinic and U.S. Clinical Pharmacology and had responsibility for Phase 1 programs in cardiology, endocrinology, inflammation, and aspects of oncology. He retired from Eli Lilly in October 2005. In November 2005 he joined the Division of Clinical Pharmacology and in March 2006, he was appointed Associate Professor of Medicine and Pharmacology.
Dr. Callaghan was instrumental in introducing pharmacogenetics to Lilly's drug development process, first through CYP2D6 and NAT2 phenotyping and later by introducing pharmacogenetic testing for NAT2, CYP2D6, CYP2C9, and CYP2C19 allelles. Within a core leadership team, he promoted a formal biomarker program that revamped Lilly's Phase 1 development strategy. His major research interests are clinical pharmacology, drug disposition and metabolism, drug interaction, pharmacogenomics, and biomarker development.
He received his M.D. in 1969 from the University of Kentucky Medical School and completed a medical residency at the University of Minnesota Medical School. He obtained board certification in internal medicine in 1972. Dr. Callaghan entered a fellowship in clinical pharmacology (1972-1974). In 1982, he received a Ph.D. in Pharmacology from the University of Minnesota. His thesis was entitled The Mechanism of Phenytoin Dose Dependency. He has given 13 invited national/international presentations and has published 26 scientific articles and 58 Final Regulatory Reports. In his academic roles, he has taught in the graduate pharmacology and clinical programs at the Universities of Minnesota and Indiana, and pharmacy programs at Purdue University. In the interval between 1974 and 1970, Dr. Callaghan was assistant chief of Clinical Pharmacology in the Department of Medicine at the Minneapolis Veterans Hospital. He commanded the 337th General Hospital and 402nd MID(S) and 476 MID(S) in Indiana before he retired in 1999 as a Colonel after 26 years of service in the US Army Reserve.
|
